CL-13

• UNSPSC Description:

  CL-13 is a butyrylcholinesterase (BChE) inhibitor, with an IC50 of 1.15 μM, and a selectivity index (SI) of 9.2 for acetylcholinesterase. CL-13 shows antioxidant activity in SH-SY5Y cells (DPPH EC50 = 47.01 μM) and has the ability to chelate metals involved in Aβ aggregation and/or oxidative stress, showing no neurotoxicity at 50 μM. CL-13 can reverse cognitive impairment caused by scopolamine (HY-N0296) without affecting the mice's motor skills[1].

• Target Antigen:

  Amyloid-β; Cholinesterase (ChE)

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cl-13.html

• Smiles:

  S=C(N/N=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1)NC2=C(C=CC=C3)C3=NC4=CC=CC=C42

• Molecular Weight:

  484.66

• References & Citations:

  [1]Gleyton Leonel Silva Sousa, et al. Discovery of novel thiosemicarbazone-acridine targeting butyrylcholinesterase with antioxidant, metal complexing and neuroprotector abilities as potential treatment of Alzheimer's disease: In vitro, in vivo, and in silico studies. Eur J Med Chem. 2025 Jan 5:281:117030.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported